Cullinan Therapeutics and Taiho Oncology have unveiled phase 3 data for their tyrosine kinase inhibitor (TKI) that could challenge Johnson & Johnson’s Rybrevant for patients with advanced non-small ...
GE HealthCare is said to be on the cusp of buying out radiopharmaceutical developer Sofie Biosciences, according to a report by the Financial Times. | GE HealthCare is said to be on the cusp of buying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results